NCT00228592终止2 期
A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-Bä, a Mixture of Two Monoclonal Antibodies, as Compared to Hepatitis B Immune Globulin in Patients Who Have Received Hepatic Allografts for Treatment of End-Stage Liver Disease Due to Hepatitis B Virus Infection
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)21 个研究点 分布在 7 个国家开始时间: 2005年9月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 试验地点
- 21
研究概览
简要总结
The purpose of this study is to compare the use of HepeX-B versus HBIg, two anti-viral drugs, in patients who have received liver transplants due to liver failure caused by Hepatitis B infection. Patients will be evaluated over a 6 month to 1.5 year period to evaluate whether or not the drugs prevent the Hepatitis B virus from infecting the new liver.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients who are 18 years of age or older,
- •Patients who are at least 6 months post first orthotopic liver transplantation (living or cadaveric donor) for treatment of end-stage liver disease due to HBV infection,
- •Patients who have received HBIg since transplantation and are on a stable regimen (i.e., same dose and frequency) for at least the 3 months immediately preceding study entry (Day 1),
- •Patients who have received treatment with an inhibitor of HBV polymerase for at least the 3 months immediately preceding study entry (Day 1),
- •Patients with undetectable HBsAg and HBV DNA concentrations on two consecutive tests at least 1 week apart during the screening period,
- •Female patients who are of childbearing potential, and males whose partners are women of childbearing potential, are required to use adequate contraception, and
- •Patients who are able to provide written informed consent.
- •Patients who successfully complete the initial 20-week treatment in the core trial are eligible for the 52-week extension phase.
排除标准
- •Women who are pregnant or breastfeeding,
- •Patients who have received another organ transplant that requires immunosuppression,
- •Patients who are co-infected with hepatitis delta virus (HDV), hepatitis C virus (HCV) and/or human immunodeficiency virus (HIV),
- •Patients with clinical conditions or diseases, which, in the judgment of the investigator, would place the patient at undue risk, interfere with study participation, or confound the results of the study, and/or
- •Patients who have participated in clinical studies in the 3 months prior to study entry.
研究者
研究点 (21)
Loading locations...
相似试验
Unknown
4 期
Twinrix Alternative Schedule StudyAntibody Response After VaccinationNCT00216229IDEWE Occupational Health Services400
已完成
2 期
A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionHepatitis B, ChronicNCT04667104Janssen Research & Development, LLC48
已完成
不适用
Comparison of effectiveness of hepatitis B revaccination schemes in healthy non-respondershepatitis B vaccine non-response10047438NL-OMON41474eids Universitair Medisch Centrum480
进行中（未招募）
1 期
Comparison of 4 different Hepatitis B vaccines in healthy persons in whom a standard hepatitis B vaccination schedule of three vaccinations did not induces a protective immune response, so-called non-responders.EUCTR2011-005627-40-NL480
Unknown
不适用
Evaluation of Antiviral Indications on Chronic HBV Infection With Different Transaminase LevelsChronic Hepatitis bALTNCT03740789First Affiliated Hospital Xi'an Jiaotong University700